JP2025542384A5 - - Google Patents
Info
- Publication number
- JP2025542384A5 JP2025542384A5 JP2025536839A JP2025536839A JP2025542384A5 JP 2025542384 A5 JP2025542384 A5 JP 2025542384A5 JP 2025536839 A JP2025536839 A JP 2025536839A JP 2025536839 A JP2025536839 A JP 2025536839A JP 2025542384 A5 JP2025542384 A5 JP 2025542384A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pharmaceutical composition
- composition according
- binds
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2033821 | 2022-12-23 | ||
| NL2033821 | 2022-12-23 | ||
| PCT/NL2023/050684 WO2024136658A1 (en) | 2022-12-23 | 2023-12-22 | Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025542384A JP2025542384A (ja) | 2025-12-25 |
| JP2025542384A5 true JP2025542384A5 (cg-RX-API-DMAC7.html) | 2026-04-21 |
Family
ID=85172568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025536839A Pending JP2025542384A (ja) | 2022-12-23 | 2023-12-22 | 少なくともｅｇｆｒに結合する抗体及び免疫チェックポイント阻害剤を使用したがんの併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4637817A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025542384A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250124833A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120583961A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023408531A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL321614A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025007322A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202432605A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024136658A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| EP2147594B1 (en) | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
| MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
| US9914777B2 (en) | 2015-07-10 | 2018-03-13 | Merus N.V. | Human CD3 binding antibody |
| TWI717401B (zh) | 2015-10-20 | 2021-02-01 | 南韓商東友精細化工有限公司 | 整合有偏光板之窗口基板、及製備該窗口基板之方法 |
| SMT202100230T1 (it) | 2015-10-23 | 2021-07-12 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Molecole di legame che inibiscono la crescita tumorale |
| CN117624324A (zh) * | 2020-12-15 | 2024-03-01 | 美勒斯公司 | 利用结合lgr5和egfr的抗体治疗癌症 |
| US20240425604A1 (en) * | 2021-10-06 | 2024-12-26 | Merus N.V. | Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr |
-
2023
- 2023-12-22 AU AU2023408531A patent/AU2023408531A1/en active Pending
- 2023-12-22 EP EP23832849.6A patent/EP4637817A1/en active Pending
- 2023-12-22 CN CN202380087705.9A patent/CN120583961A/zh active Pending
- 2023-12-22 JP JP2025536839A patent/JP2025542384A/ja active Pending
- 2023-12-22 KR KR1020257021503A patent/KR20250124833A/ko active Pending
- 2023-12-22 WO PCT/NL2023/050684 patent/WO2024136658A1/en not_active Ceased
- 2023-12-22 TW TW112150387A patent/TW202432605A/zh unknown
-
2025
- 2025-06-19 IL IL321614A patent/IL321614A/en unknown
- 2025-06-20 MX MX2025007322A patent/MX2025007322A/es unknown